well. O ver the next seve ra l months, whil e she co nt inue d to tak e 60 mg of fiuox etine da ily, Ms. A did well. Sh e became more socia l, was helping her family as she had don e before the d epression, and eve n returned to work .
Aft er five months of treatm en t with 60 mg of fluoxetin e dai ly, Ms. A had sto ppe d the medi cation , and dropped out of treat me nt. She remai ned asymptomatic fo r a no t her four months, wh en she red evelop ed depressive sym pto ms, a nd was see n ag a in a t o ur outpat ient clinic. On exa m Ms. A had depress ed mo od , psychomotor retardation , low e ne r!:, ')" level , seve re anhedonia , initial a nd middle in somnia, hop el essn ess, helplessn ess, self -depreciati on , a nd ruminative th ou ght s. Her cog nit ive exa m was normal , a nd s he had no psych o tic sym pto ms . Flu ox etine was rest art ed and titrat ed to 80 m g/day ove r th e next 2 mo nt hs . She re m a ined on 80 mg/d ay for 5 weeks, without significa nt improvem ent , a t whi ch tim e bu pro pio n SR was added to her fluoxetin e regim en , at 50 mg/d ay, Aft er 3 da ys bupropion was incr eased to 100 mg/day. On th e 3rd da y of treatm ent with bupropion 100 m g a day, M s. A devel o ped ideas tha t peopl e were talking a bout her, st ra ng ers o n th e st ree ts were wat chin g her, a nd she felt reluctant to leav e he r hou se. On th e 7'h day of bupropion tr ea tment M s. A was re-evalu a ted as an outpatient. H er exa m at th at tim e reveal ed no significa n t impairm ent in o rie nta tion, conce n tra t ion, or m emory. Sh e had delusion al ideas of refe ren ce (as a bove ) a nd no insight in to her psych otic sym ptoms. She rep ort ed her mood to be bett er, a nd he r affec t was less depress ed, with no hop el essn ess, or helplessn ess. H er e ne rgy was a lso bett er, as was her a p pe tite . No manic sym ptoms were obs erved . The bupropion was di scontinu ed , a nd Ms. A was give n risperidone 1.5 m g bid . Sh e took only on e do se, th en s topped th e a ntipsycho t ic m edi cation seco ndary to severe se da t ion. O ver t he next 7 days, he r psycho tic sym ptoms resolved co m ple tely, but she began to ex pe rie nc e a n exace rba tion of her dep ress ive sym ptom s. Three week s late r her fluox etine wa s stopped, and Ms. A was switched to ve nla fax in e. O n follow up aft er 3 months , Ms . A had mild depressiv e sym pto ms, no psych oti c symp toms, an d no cog n itive impairment.
The mech anism of acti on of buprop ion is not well unders tood ( I); however, it is beli eved th at th e a n tide pressa nt effec t, an d possibly so me sid e effec ts, a re du e to nor ep in ephrine turnover, and to less er ex te nt, dopamin e reupt ak e blockad e ( 1,2) . T he re have been seve ra l case rep orts of a ppa re nt bupropion-associat ed psych osis (2-11), howeve r , mo st of th e patie nt s wh o developed psych osis whil e taking bu pr op ion had a history of psych osis pri or to buprop ion treatment. Som e of th es e rep orts des cribe not o nly pathology of th ou ght pro cesses, a nd perceptual di sturbances, but al so definit e cog nitive impairm ent with clo ude d cons cious ness . W e were abl e to id entify only 3 report s of psychotic sym pto ms in th e a bse nce of cog nit ive im pa ir me nt in non-predi sposed ind ividual s followin g buprop ion treatm e nt (2 cases of hallucina t io ns, a nd one cas e of delusion s a nd hallu cin ation s) (9-11). T o ou r kn owled ge, no rep orts described pure delusional psych osis without perceptual di sturban ces. Addi t iona lly, all of t he reports of bupropion-induced psychosis a nd bupropion-induced delirium involved dail y doses in th e range of 300 mg a nd a bove (2-10) . In our patient , th e maximum dose d id not exceed 100 m g/d ay of bupropion SR .
Bupropion undergoes ex te nsive hep atic metaboli sm , m ainl y t hro ugh th e C YP 45 0 IIB6 a nd IIIA 3/4 syst ems (15) ; th e latt er of whi ch is known to be su ppressed by fiuox etin e ( 14, 15) . Bupropion do cs not appear to be metabolized by IID 6 iso en zym es; however, th ere a rc so me dat a th at bupropion and it s metabolites may in hibi t IID 6 ( 14) , whi ch is a secon dary met ab olic pathway for fluox etine. Bupropion met ab olites m ay be el eva ted in people wit h he pa tic di sease a nd in th e e lde rl y, whi ch ma y be contributory to side effec ts ( 10, 15) . In our pa t ie nt , th e significa n t improve m ent in he r moo d bega n afte r several d ays of treatment wit h bupropion, at approx ima te ly th e same ti m e th at she s tarte d experie nc ing de lus ions. Bo th her mood im p rovem ent , as well as psych otic sym p toms, migh t be a tt rib uted to an inc reased leve l of bupropion m et abolites.
Alte rna tiv ely, th e ph en om ena of d ru g-a ssociated delusions might be ex pla ine d by ser oton e rgic mec ha nisms . Flu oxetine inc reases ve n tra l stria ta l serotoni n ( 17), stimulating 5-HT3 rece ptor-me d ia te d d op am in e rel ea se in th e ventral stria ta l regio n, wh ich may le ad to psych osi s ( 18) . U nde rle ider a nd Pechnick ( 19) , in reviewi ng th e mecha nisms of a ct ion of hall ucinogens, co ncl ude d th at th ese age n ts work throu gh effects a t 5-HT2 receptor s. However , Pie rce and Peroutka (20) sugges te d th at ac tion a t 5-I-IT IC, a nd not 5-1-1'1'2 recept or s, m ay account for th e hallucin ogenic pr op erties. Am on g severa l report s d escribing Iluox etin e a nd psych oses, (18,2 1-24) we were a ble to identify o nly one case of possibl e f1u ox etin e-induced persecutory d e lusions in a patient who did not have pr evious hi st or y of psych osis (20); as we ll as 3 re ports of visual hallucinosis (22) (23) (24) . One of those pati ent s wa s a lso taking L-dopa, a nd a no t he r d evelop ed visua l hallucinosis aft er d extrom ethorphan had be en ad de d to her regimen. Althou gh it is pos sibl e to attribut e Ms. A's psychotic sym ptoms to e leva te d level s of f1u ox etin e, ca used by bupropion-associat cd 2D 6 inhibit ion , we beli eve that it is unlikely, s ince th e C YP IID6 system is onl y a minor pathway for f1uoxetine ( 13) .
One other possible ex pla na tio n for th e d evelopm ent of psych oti c sym ptoms in Ms. A wou ld be a so-ca lle d "sc h izoa ffcc tive evolu t ion" in th e co u rse of her a ffec tive illness . Although Ms. A had a fa m ily hist or y of sc h izo p h ren ia a nd de p ress ion, we th ink th is is ex t re m ely un likely, du e to th e sho rt sym ptomat ic per iod of th e d elusion s (a bo u t 8 days), t hei r di sa ppea ra nce wi t ho u t specific an tipsyc ho tic trea tme nt , th e obvious tempo ral rel a tio nsh ip wit h t he initiation of bupropion tr ea t m e nt , a nd th e lack of negative symp to ms be tween he r de pressive e pisodes .
Of add it ional in terest wa s Ms. A's initial res po nse to Iluo xet in e, b u t lack of response to th e sa me m edi cation wh en it wa s rest a rt ed , eve n at incr ea sed dose . The d eve lopm ent of tol erance to th e therapeutic effec ts of SSRI 's, whi ch Goodnick a nd Go lds tei n (25) hav e te rm ed " ne u ro p hys iolog ica l tole ran ce" , is a well-know n ph en om en a , an d has be e n reported el sewh er e (25 -3 1) . Fava e t a l (26) in th eir s t udy of re-initiation of ant ide pressan t t reat m en t in patient s wh o pr eviously resp onded to fluox ctine, but lat er we re switc he d to placeb o a nd rela pse d, found that 38% of th e patients did not resp ond to th e re -in it ia tion of fl uoxe tin e. Mi ch el son e t a l (29 ) rep or ted th at Iluox e tin e occasiona lly lost e fficacy afte r 9 months of co n tin ued t reatm ent , foll owin g res po nse to 12-14 week s of initial treatm ent. Fava e t a I., (30) rep ort ed t ha t rela pse o r recurren ce of d epressive sym pto ms occu rr ing in pa tie n ts receivin g co nti n ua tion or mainten an ce th erapy with Huoxet in e 20 rug/d ay, ca n be tr ea ted e ffectivel y by increasing the dos e to 40 rug/day. Conversely, Cain (31) postulating that overm edi cation with Iluoxet ine might a ppear as a response failure , report ed 4 patients who con tin ue d to d et eri or at e wh en their dose of f1u ox etin e was raised, but that sym p to ms improved dram aticall y during sys te ma tic tri al s of lowe r do se s. C a in noted th at higher d oses of Iluox etine ma y co rre la te with high plasm a co nce n tra tion of norfluox ct in e, th e ac t ive m etabolite of fluox etine, wh ich wa s som e times as socia te d with a poor clinical response. (3 1).
The m ech anism of this loss of e fficacy of SSRI's, a nd flu ox et in c in particul a r, rema ins unclear. One hypothesis sugges ts th at long-t er m trea t m ent with Iluoxet iu e may ca us e a rel ati ve dop amine d eficien cy, whi ch m ay resp ond to tr e atm ent wit h pos tsy na p tic do pam ine ago nists (33) . Our case m ay lend sup port to this th eor y, surrou nd ing th e fac t th a t Ms. A d evel op ed d elusion al idea s, but a lso had rep ort ed so me imp roveme nt in he r mood.
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One final possibl e explana t ion for Ms. A' s treatm ent resist an ce may be th e cont ribut ion of her medi cal cond itions, di ab et es in particul a r. Her di ab et es was not we ll controlled, based on th e hem oglobin Al c level, as well as incr eased cholesterollH DL and low HDL. Howeve r, th c rest of her laboratory exa ms wer e normal , so it see ms unlikely th at her ini tia l lack of respon se to fluoxetine ma y be a tt r ibute d to her medi cal cond it ion. Also, th e re a re som e reports th at fluoxetine has prov en effec t ive as a n a nt ide pressa n t in th e tr eat m ent of depression assoc ia te d with se rous ph ysical illn esses, including di ab et es (34) .
\Ve pr esent th e case of a 45 yea r old wom an with depression unresponsive to fluoxet in e, whos e depression responded to th e adj unc tive addition of bupropi on , but who developed fra nk psychosi s soon aft er initiation of bupropion in low-mod erat e dose. We sug ges t a ca utious approach in th e concurrent use of bupropion and substan ces th at int erfer e with its metabolism.
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